VisionCare, Inc.
11
3
3
2
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 100/100
27.3%
3 terminated/withdrawn out of 11 trials
40.0%
-46.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 2 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
International Study of the SING IMT™ Prosthesis in Pseudophakic patiEnts With Stable Moderate to Profound Bilateral Central vIsion Impairment Due to adVancEd AMD / PERSPECTIVE Study
Role: lead
Post-market Clinical Investigation of the SING IMT System, Model NG SI IMT 3X in Patients With End-stage Age-related Macular Degeneration
Role: lead
Multicenter Clinical Study of the SING-IMT in Patients with Late-stage AMD
Role: lead
A Study of the SING IMT in an Israeli Cohort
Role: lead
Study of WA-NG (NG-IMT) Telescope Prosthesis in Patients With End-stage Age-related Macular Degeneration
Role: lead
Study of WA-NG Telescope Prosthesis in Patients With End-stage Age-related Macular Degeneration
Role: lead
Post-Approval Study of the Implantable Miniature Telescope
Role: lead
Telescope Exchange Study
Role: lead
A Long-Term Monitoring Study of the IMT-002 Patients
Role: lead
Study of WA-NG Telescope Prosthesis in Patients With End-stage Age-related Macular Degeneration
Role: lead
A Study of an Implantable Miniature Telescope in Patients With With End-Stage AMD
Role: lead
All 11 trials loaded